Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma-Reference-Cited by-同舟云学术

Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma

Published:2020-08 Issue:8 Volume:26 Page:1414-1424
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Holstein Sarah A.,Suman Vera J.,Owzar Kouros,Santo Katelyn,Benson Don M.,Shea Thomas C.,Martin Thomas,Silverman Margarida,Isola Luis,Vij Ravi,Cheson Bruce D.,Linker Charles,Anderson Kenneth C.,Richardson Paul G.,McCarthy Philip L.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference61 articles.

1. Role of stem cell transplant and maintenance therapy in plasma cell disorders;McCarthy;Hematology Am Soc Hematol Educ Program,2016

2. Single versus double autologous stem-cell transplantation for multiple myeloma;Attal;N Engl J Med,2003

3. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study;Cavo;J Clin Oncol,2007

4. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial;Mai;Br J Haematol,2016

5. Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial);Cavo;J Clin Oncol,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

4. Values of Immunoglobulin and Complements for Evaluating Treatment Outcomes of Patients with Multiple Myeloma;CLIN LAB;2023

5. Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions;Oncology and Therapy;2022-02-01